|会社名||Amgen In （アムジェン）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 アムジェン(Amgen Inc.)はバイオテクノロジー会社である。同社は多様なヒト治療法を発見・開発・製造・提供する。同社はヒト治療事業を運営する。同社の製品ポートフォリオはNeulasta（ペグフィルグラスチム）、Aranesp（ダルベポエチンアルファ）・EPOGEN（エポエチンアルファ）等の赤血球産生促進剤（ESAs）、Sensipar/Mimpara（シナカルセット）、XGEVA（デノスマブ）、Prolia（デノスマブ）及びNEUPOGEN（フィルグラスチム）、並びにKYPROLIS（カルミゾミブ）、Vectibix（パニツムマブ）、Nplate（ロムリプスチム）、Repatha（エボロクマブ）、BLINCYTO（ブリナトモマブ）、IMLYGIC（タルミモジュラーラパーパープ）、Corlanor（イバブラジン）など他の市販製品を含む。同社は腫瘍/血液学、心臓血管疾患および神経科学の分野における重篤な疾患の治療のためのヒト治療法を提供し、反復性片頭痛治療用Erenumab、骨髄異形成症候群治療用Aranesp、急性リンパ芽球性白血病治療用BLINCYTOおよび転移性メラノーマ治療用IMLYGICを含むフェーズⅢの製品候補を提供する。 アムジェンはバイオ医薬品メ―カ―で、高度な細胞生物学と分子生物学に基づく治療薬の開発、製造、販売を展開する。特にがん、腎臓病、炎症、腫瘍学の分野での治療薬の開発に注力、製品は診療所、透析センタ―、病院に販売される。主要製品は、がん化学療法中の患者や透析患者向けの貧血症治療剤｢アラネスプ｣、白血球減少症治療剤｢ニュ―ラスタ｣など。 Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.|
|本社所在地||One Amgen Center Drive Thousand Oaks CA 91320-1799 USA|
|代表者氏名||Robert A. Bradway ロバート・A・ブラッドウェイ|
|代表者役職名||Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Amgen Inc. revenues increased 3% to $11.61B. Net income increased 9% to $4.61B. Revenues reflect Rest of the World segment increase of 9% to $2.51B Other segment increase of 18% to $591M. Net income benefited from Other decrease from $50M (expense) to $22M (income) Foreign currency contracts increase from $14M to $33M (income). Dividend per share increased from $2.30 to $2.64.|
Dow soars toward best 2-day gain in 2 1/2 years 2022/10/04 15:53:48 MarketWatch
The Dow Jones Industrial Average bulled 750.52 points, or 2.5% higher, in midday trading Tuesday with all 30 components trading higher. Together with Monday''s 765.38-point gain, the two-day rally of 1,516.59 points puts the blue-chip barometer on track for the best two-day performance since it climbed a total of 1,601.33 points on April 6 and April 7 of 2020. On Tuesday, the best performers were shares of Salesforce Inc. , up 5.8% and Boeing Co. , which climbed 5.1%. The Dow''s most active stock was Apple Inc. , which ran up 2.0%, while the worst performer was Amgen Inc.''s stock, which gained 0.7%. The Dow''s rally took the index back above the June closing low, a little more than a week after closing below it on Sept. 23 to take the current bear market to a new phase. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer 2022/10/04 12:00:00 Accesswire
Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs CORALVILLE, IA / ACCESSWIRE / October 4, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer (CMO). "Markus joins Viewpoint with an impressive track record of building and leading successful oncology programs," said Thijs Spoor, CEO of Viewpoint Molecular Targeting. "His broad, global experience across many tumor types at all stages of clinical development make him the ideal candidate to join Viewpoint as CMO. I am thrilled to have Markus on our management team and look forward to working together." Dr Puhlmann has 20 years of experience in oncology drug development in solid and liquid tumor indications.
Peptide Therapeutics Global Market Report 2022 2022/10/03 13:50:00 GlobeNewswire
Major players in the peptide therapeutics market are Amgen, Inc. , Pfizer, Inc. , Bristol-Myers Squibb Company, Sanofi, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd. , Bachem Holding AG, Takeda Pharmaceutical Company Limited, Galena Biopharmaceuticals, Arch Biopartners, Arch Biopartners Inc. Major players in the peptide therapeutics market are Amgen, Inc. , Pfizer, Inc. , Bristol-Myers Squibb Company, Sanofi, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd. , Bachem Holding AG, Takeda Pharmaceutical Company Limited, Galena Biopharmaceuticals, Arch Biopartners, Arch Biopartners Inc.
Monday’s Top Analyst Upgrades and Downgrades: Amgen, CrowdStrike, Intuit, Micron Technology, Microsoft, Nike, Roblox, Wells Fargo and More – 24/7 Wall St. 2022/10/03 12:51:40 24/7 Wall street
Monday''s top analyst upgrades and downgrades included Amgen, CarMax, Centene, CrowdStrike, Intuit, Micron Technology, Microsoft, Nike, NOV, Roblox, Unity Software and Wells Fargo.
Amgen powers up despite negative pressures - Analysis - 29-09-2022 2022/09/29 12:45:35 Economies
Amgen''s stock (AMGN) surged in the intraday levels, amid positive signals from the RSI after …
Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer (NASDAQ:AMGN) 2022/09/15 17:36:15 Seeking Alpha
Lung cancer drugs from Amgen and Mirati can barely be separated on efficacy. Read why AMGN has first mover advantage but MRTX may have a slight edge.
Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial 2022/09/15 16:04:05 Seeking Alpha
Sorrento Therapeutics (SRNE) said that patients with rheumatoid arthritis who received Amgen''s (AMGN) Enbrel (etanercept) though the company''s Sofusa Lymphatic Drug Delivery…
Amgen (AMGN): Growing Doubts About The Future 2022/09/14 20:36:54 Seeking Alpha
Amgen''s profitability has been struggling since 2018. Huge buybacks and rising dividends are weakening the financial structure too much. Read more here.
Wednesday’s Top Analyst Upgrades and Downgrades: Amgen, AppLovin, Dell, Dow, Marvell Technology, PayPal, RingCentral, Shopify, SoFi, Western Digital and More – 24/7 Wall St. 2022/09/14 12:54:19 24/7 Wall street
Wednesday''s top analyst upgrades and downgrades included Amgen, AppLovin, Blue Owl Capital, Dell Technologies, Dow, Marvell Technology, PayPal, RingCentral, Shopify, SoFi Technologies, Twilio, Western Digital, WiPro and Wolfspeed.
AMGN stock drops to six-month low amid latest challenges to pipeline (NASDAQ:AMGN) 2022/09/13 20:38:58 Seeking Alpha
Amgen (AMGN) shares reached the lowest level since March as Wall Street reacted to the company''s latest update on KRAS inhibitor Lumakras, while Bristol Myers (BMY) introduced a new…
Amgen''s Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer 2022/04/11 16:13:05 Benzinga
Amgen Inc (NASDAQ: AMGN ) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, … Full story available on Benzinga.com
Amgen und Biogen: Schlagen diese beiden Biotech-Urgesteine bald zurck? 2022/04/11 16:00:06 FinanzenNet
piframe title="Amgen und Biogen Schlagen diese beiden Biotech-Urgesteine bald zurck?" width="475" height="267" src="https://www.youtube.com/embed/abu7F90gWEM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; …/p
TSX Steps Back from All-Time Highs 2022/04/06 20:23:00 Baystreet Canada
Equities in North America displayed their nerves Wednesday, with central banks openly discussing rate hikes for the very near future. The TSX Composite Index lost 142.23 points to conclude midweek Wednesday at 21,788.60. The Canadian dollar fell 0.31 cents to 79.79 cents U.S. Tech proved the biggest anchor on the index, with Lightspeed POS down $3.07, or 7.7%, to $36.63, and Shopify sagged $54.61, or 6.3%, to $823.86. Real-estate was also a worry, as InterRent REIT dropped 57 cents, or 3.8%, to $14.57, while Allied Properties REIT faltered $1.45, or 3.1%, to $44.69. In energy, Whitecap Resources moved earthward 48 cents, or 4.6%, to $9.88, while Vermilion Energy slid $1.58, or 5.9%, to $25.27. Utilities was strongest fop the gainers, as Transalta copped 50 cents, or 3.8%, to $13.57, while Boralex advanced $1.96 or 3.4%, to $41.56. Communications became green in the afternoon, with Quebecor tacking on 76 cents, or 2.5%, to $31.27, while Cogeco Communications moved forward $1.51, or 1.4%, to $105.86.
Fed Tightening Weighs on Markets 2022/04/06 20:23:00 Baystreet Canada
Stocks fell for a second day on Wednesday and rates soared to new heights as the Federal Reserve gave more guidance on how fast it will tighten monetary policy to fight inflation, raising concerns it may slow the economy. The Dow Jones Industrials plummeted 144.67 to end the session at 34,496.51. The S&P 500 dumped 43.97 points to 4,481.15 The NASDAQ Composite wilted 315.35 points, or 2.2%, to 13,888.82. The Fed’s release of its meeting minutes indicated on Wednesday afternoon that officials “generally agreed” it should shrink its balance sheet by $95 billion per month. The minutes also showed the central bank was considering larger rate hikes than its usual 25-basis-point, or quarter-point, increments. As the Fed hikes rates, investors have begun searching for stocks with stable profits and shying away from those offering future growth. That includes the utilities, health care and consumer staples sectors — which continued to climb Wednesday, with Amgen and Johnson & Johnson rising about 2% each.
Is Amgen Inc. (NASDAQ: AMGN) Still A Good Investment? 2022/04/06 17:00:00 Stocks Register
Amgen Inc. (NASDAQ:AMGN) traded at $250.15 at last check on Wednesday, April 06, made an upward move of 2.29% on its previous day’s price. Looking at the stock we see that its previous close was $244.56 and the beta (5Y monthly) reads 0.64 with the day’s price range being $243.74 – $248.75. The company has … Is Amgen Inc. (NASDAQ: AMGN) Still A Good Investment? Read More »
関連キーワード （医薬品 米国株 アムジェン AMGN Amgen Inc.）